Literature DB >> 3806086

Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates.

J D Elsworth, D J Leahy, R H Roth, D E Redmond.   

Abstract

In a large number (91) of vervet monkeys, correlation coefficients were determined between homovanillic acid (HVA) concentrations in four brain areas. Significant correlations existed between dorsal frontal cortex and orbital frontal cortex and between putamen and caudate nucleus. However, no significant correlations existed between either cortical area and the basal ganglia areas. Correlations were tested between CSF and plasma HVA and between these fluids and brain regions. The only significant relationship found was between CSF and dorsal frontal cortex, after possible treatment effects were statistically removed. The assumption that primate CSF HVA concentration necessarily reflects basal ganglia HVA concentration is questioned and furthermore, the results suggest that HVA from cortex contributes significantly to that in cisternal CSF. Raw plasma HVA measurements (even when uninfluenced by diet or anesthetic) appear to be of limited value in gauging central dopamine metabolism and turnover.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806086     DOI: 10.1007/bf01244639

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  20 in total

1.  Regional distribution of dopamine metabolites in human and primate brain.

Authors:  N G Bacopoulos; J W Maas; S E Hattox; R H Roth
Journal:  Commun Psychopharmacol       Date:  1978

2.  [Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS].

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz
Journal:  Wien Klin Wochenschr       Date:  1966-06-10       Impact factor: 1.704

3.  Dopamine and its metabolites in human peripheral nerves: is there a widely distributed system of peripheral dopaminergic nerves?

Authors:  Z Lackovic; J Kleinman; F Karoum; N H Neff
Journal:  Life Sci       Date:  1981-08-31       Impact factor: 5.037

4.  On the intracerebral origin of homovanillic acid of the cerebrospinal fluid of experimental animals.

Authors:  R Papeschi; T L Sourkes; L J Poirier; R Boucher
Journal:  Brain Res       Date:  1971-05-21       Impact factor: 3.252

5.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

6.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  R S Burns; P A LeWitt; M H Ebert; H Pakkenberg; I J Kopin
Journal:  N Engl J Med       Date:  1985-05-30       Impact factor: 91.245

7.  Contribution of plasma homovanillic acid (HVA) to urine and cerebrospinal fluid HVA in the monkey and its pharmacokinetic disposition.

Authors:  M A Elchisak; R J Polinsky; M H Ebert; K J Powers; I J Kopin
Journal:  Life Sci       Date:  1978-12-04       Impact factor: 5.037

8.  Relative importance of 3-methoxy-4-hydroxyphenylglycol and 3,4-dihydroxyphenylglycol as norepinephrine metabolites in rat, monkey, and humans.

Authors:  J D Elsworth; R H Roth; D E Redmond
Journal:  J Neurochem       Date:  1983-09       Impact factor: 5.372

9.  Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems.

Authors:  M J Bannon; E B Bunney; R H Roth
Journal:  Brain Res       Date:  1981-08-10       Impact factor: 3.252

10.  Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey).

Authors:  N G Bacopoulos; D E Redmond; J Baulu; R H Roth
Journal:  J Pharmacol Exp Ther       Date:  1980-01       Impact factor: 4.030

View more
  9 in total

Review 1.  Chronic stress, allostatic load, and aging in nonhuman primates.

Authors:  Dario Maestripieri; Christy L Hoffman
Journal:  Dev Psychopathol       Date:  2011-11

Review 2.  A new approach to biochemical evaluation of brain dopamine metabolism.

Authors:  I J Kopin; J H White; K Bankiewicz
Journal:  Cell Mol Neurobiol       Date:  1988-06       Impact factor: 5.046

Review 3.  A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.

Authors:  Eleanor H Simpson; Christoph Kellendonk; Eric Kandel
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

4.  CSF monoamine metabolite concentrations vary according to age, rearing, and sex, and are influenced by the stressor of social separation in rhesus monkeys.

Authors:  J D Higley; S J Suomi; M Linnoila
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 5.  Modeling dopamine dysfunction in autism spectrum disorder: From invertebrates to vertebrates.

Authors:  Gabriella E DiCarlo; Mark T Wallace
Journal:  Neurosci Biobehav Rev       Date:  2021-12-11       Impact factor: 8.989

6.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

7.  Regional studies of serotonin and dopamine metabolism and quantification of serotonin uptake sites in human cerebral cortex.

Authors:  B Parsons; A Roxas; Y Y Huang; A Dwork; M Stanley
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 8.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD.

Authors:  Evan Taerk; Natalie Grizenko; Leila Ben Amor; Philippe Lageix; Valentin Mbekou; Rosherie Deguzman; Adam Torkaman-Zehi; Marina Ter Stepanian; Chantal Baron; Ridha Joober
Journal:  BMC Med Genet       Date:  2004-12-21       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.